MOMA's mission is all about harnessing the power of highly dynamic proteins - but what are they? Highly dynamic proteins - often referred to as "molecular machines” - drive many cellular processes that underlie human disease. They are historically hard to drug because of their ability to shapeshift. We're focusing on the potential of this target class with two wholly-owned lead oncology assets, alongside a strong pipeline of high-value pre-clinical candidates so we can bring a new generation of precision therapeutics to patients in need. Learn more about highly dynamic proteins below and at momatx.com.
MOMA Therapeutics’ Post
More Relevant Posts
-
Wonder what we are up to at MOMA? We are focused on highly dynamic proteins. Learn more below
MOMA's mission is all about harnessing the power of highly dynamic proteins - but what are they? Highly dynamic proteins - often referred to as "molecular machines” - drive many cellular processes that underlie human disease. They are historically hard to drug because of their ability to shapeshift. We're focusing on the potential of this target class with two wholly-owned lead oncology assets, alongside a strong pipeline of high-value pre-clinical candidates so we can bring a new generation of precision therapeutics to patients in need. Learn more about highly dynamic proteins below and at momatx.com.
-
How does CHARMED from Sygnature Discovery work in action? Using the clinically relevant oncology target SHP2 in the Ras pathway as a model, we showcase our capabilities in degrader synthesis and the development of high-quality in vitro assays for compound profiling. We demonstrate this through a customer project, where potent degraders were swiftly identified. Learn more from Dr Steve Young (VP of Business Development) and Dr Hiroki Wada (Business Development Manager) at the poster presentation at EFMC-ACSMEDI MedChem Frontiers in Utrecht, April 8-11. Can’t make the event? Download our digital poster: https://lnkd.in/eN3iQ68U #medicinalchemistry #CHARMED #targetedproteindegradation #drugdiscovery
-
-
We can't believe we are almost at the end of #HUPO2024! Of course, our team is going out with a bang with no less than 1 oral presentation, 4 scientific posters, and our lunch seminar. Today's topics include: ➡️High-throughput and ultra-deep #proteomics powered by our P2 Enrichment System, showcasing its application in cancer type classification (oral presentation OP-76) ➡️ Input normalization and PTM stoichiometry calculations in #Spectronaut (poster P-III-0800) ➡️ An introduction to the Digital Proteome - a resource for target expression across 22 tissues in human and preclinical species (poster P-III-0832) ➡️ Using LiP-MS for target identification, selectivity profiling, and binding site mapping of small molecule and peptide drugs (poster P-III-0866) ➡️ Deep proteomic profiling of matched CSF and #plasma samples for aging biomarker discovery (poster P-III-0874) 🔗Learn more and register for our lunch seminar here: https://lnkd.in/dh8GAqJU #DrugDevlopment #TrueDiscovery #TrueTarget #MassSpectrometry
-
-
Roger Waltzman, Indaptus Therapeutics (NASDAQ: INDP) CMO, explains how they evaluate the effectiveness of #Decoy20. Beyond aiming for a cure, their trials are advancing their understanding of how the immune system works. Their studies rigorously assess tumor response, immune cell responses, survival rates, and quality of life improvements. By analyzing biomarkers, they also identify who might benefit most from their therapies, striving for regulatory approval and global access. Thier mission is to revolutionize #cancertreatment! #IndaptusTherapeutics #CancerResearch #Decoy20 #biotech https://lnkd.in/gYRNhfsK
-
We’ve made significant advancements to our OrganoidXplore™ platform 🌟 Expanded Model Library: We now have a total of 64 models in our comprehensive cancer panel, covering 7 indications. 🌐 Enhanced KRAS Mutant Models: We’ve added 7 new KRAS mutant models, bringing the total to 26 KRAS mutant models. This expansion allows for more detailed insights into mutation-driven cancers. 🔍 Flexible Model Selection: Our platform offers flexible model selection, starting from 20 models. This flexibility ensures that you can design your own panel tailored to your specific research needs. OrganoidXplore™ continues to be the first large panel-based organoid screening service, unique to Crown Bioscience. It accelerates drug discovery and development, from lead compound identification to selecting the right models and indications for meaningful results. Join us on this journey to revolutionize drug discovery and development! #DrugDiscovery #CancerResearch #Organoids #KRAS #Biotech #Innovation #CrownBioscience
-
-
#AI #Pharma It's not that I do not appreciate the buzz around LLMs. They are absolutely cool - just check out the recent (open-sourced!) Llama 3.1 released my Meta just a few day ago. And yes, there's a lot of cross-pollination happening between different sectors and domains in AI. But what really keeps me motivated, working, studying, and training around the clock are somewhat different kind of stories - from the healthcare, pharmaceuticals, chemistry. Take a moment to explore what the folks from Leash Bio are doing right now. There's so much hidden value, impact, and life-changing potential here! If I were running a VC fund these days - I'd definitely go into this kind of ventures...
#AI #Chem #Pharma #DEL Just won the first place in the NeurIPS small molecule drug prediction contest sponsored by AlphaMa and Top Harvest Capital - out of some 2,000 participants from all around the world. Kind of little moment of glory, you know? Unfortunately, with all these things going on - HEC, Northwestern, a couple of prospective business ventures - I missed the most important part of any contest: the acceptance speech. So, until next time, probably. Now, with summer approaching the equator, it's time to try out the Skin Cancer prediction contest by the International Skin Imaging Collaboration. Did you know that the head and neck area is twice as likely to develop skin cancer compared to other body areas?
-
An Allosteric Pan-Mutant-Selective PI3Kα Inhibitor Without Hyperglycemia in Preclinical Models | https://lnkd.in/gu9AyiXH RLY-2608 is an oral, mutant-selective PI3Kα allosteric inhibitor from Relay Therapeutics, targeting a cryptic pocket near the ATP-binding site. Given the challenges and toxicities associated with WT PI3Kα inhibition—such as hyperglycemia and rash—there's an increasing need for next-generation, mutant-selective PI3Kα inhibitors. Relay Therapeutics recently shared promising interim data from the Phase I ReDiscover trial in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer. Explore this case study on RLY-2608 to dive into the discovery strategy, mechanisms driving mutant selectivity, its position in the competitive landscape, preclinical activity, recent clinical developments, and more. Full Article: https://lnkd.in/gu9AyiXH
-
Our expert oncology-focused scientists use advanced PKPD modelling to bridge the gap between pre-clinical studies and clinical trials, ensuring precise dose selection for the best outcomes. 🧬✨ By harnessing sophisticated mathematical modelling techniques, we empower drug developers to make informed, evidence-based decisions. Less lab time, fewer animal studies, more accuracy. Ready to fast-track your drug's journey to success with fewer risks? Reach out to our friendly team today! https://lnkd.in/eYmCKgmX #Cancer #DrugDevelopment #VirtualTumour #Immunotherapy #CancerDrugs #CancerSimulation #CombinationTherapies #QSP #MathematicalModelling #PKPD #MechanisticModelling #Oncology #ClinicalTrials #ResearchandDevelopment #CancerResearch #BioTech #StatisticalModelling #MachineLearning #Pharma #PYC
-
-
Dr. Michael Newman, Indaptus Therapeutics (NASDAQ: INDP) Founder, Chief Scientific Officer, and lead author, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy #bacteria can activate a wide range of innate and adaptive human #immunecells involved in fighting tumors. This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad #immuneactivation, as evidenced by transiently increased levels of many key #cytokines and #chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a #multifaceted #immunotherapy.” https://lnkd.in/gZfkj2DR
-
-
Research published in the peer-reviewed journal Nature demonstrated the ability of SNAP-CAR to provide a powerful adaptor strategy for fully programmable targeting of engineered cells to multiple antigens, including CD19. Based on these findings, Coeptis Therapeutics and the team at the University of Pittsburgh plan to expand the development of the SNAP-CAR platform to target the #autoimmune diseases in addition to #hematologic and solid tumors. Read the research here: https://lnkd.in/ggvUweaJ #Biotech #Science #CARTtherapy
-
🔎Proven Biotech/Life Science Talent Specialist with 7 years' Experience | Connecting Top Talent with Cutting-Edge Opportunities
2moamazing work MOMA Therapeutics